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Abstract
Background: Tardive dyskinesia (TD) is a major limitation of older antipsychotics. Newer
antipsychotics have various other side effects such as weight gain, hyperglycemia, etc. In a previous
study we have shown that an indolamine molecule expresses a moderate binding affinity at the
dopamine D2 and serotonin 5-HT1A receptors in in vitro competition binding assays. In the present
work, we tested its p-toluenesulfonyl derivative (TPBIA) for behavioral effects in rats, related to
interactions with central dopamine receptors and its antioxidant activity.
Methods: Adult male Fischer-344 rats grouped as: i) Untreated rats: TPBIA was administered i.p.
in various doses ii) Apomorphine-treated rats: were treated with apomorphine (1 mg kg-1, i.p.) 10
min after the administration of TPBIA. Afterwards the rats were placed individually in the activity
cage and their motor behaviour was recorded for the next 30 min The antioxidant potential of
TPBIA was investigated in the model of in vitro non enzymatic lipid peroxidation.
Results: i) In non-pretreated rats, TPBIA reduces the activity by 39 and 82% respectively, ii) In
apomorphine pretreated rats, TPBIA reverses the hyperactivity and stereotype behaviour induced
by apomorphine. Also TPBIA completely inhibits the peroxidation of rat liver microsome
preparations at concentrations of 0.5, 0.25 and 0.1 mM.
Conclusion: TPBIA exerts dopamine antagonistic activity in the central nervous system. In
addition, its antioxidant effect is a desirable property, since TD has been partially attributed, to
oxidative stress. Further research is needed to test whether TPBIA may be used as an antipsychotic
agent.
Background
It is well established that compounds which interact with
central dopamine receptors have therapeutic potential in
the treatment of conditions like Parkinson's disease and
psychotic disorders. For the later treatment, it is known
that tardive dyskinesia (TD) is a major limitation of
chronic antipsychotic drug therapy at least with older
(typical) antipsychotics.
Published: 07 January 2004
Annals of General Hospital Psychiatry 2004, 3:1
Received: 29 November 2002
Accepted: 07 January 2004
This article is available from: http://www.general-hospital-psychiatry.com/content/3/1/1
© 2004 Zika et al; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media 
for any purpose, provided this notice is preserved along with the article's original URL.Page 1 of 7
(page number not for citation purposes)
Annals of General Hospital Psychiatry 2004, 3 http://www.general-hospital-psychiatry.com/content/3/1/1There is increased awareness of the different ways in
which this condition manifests itself and the variety of
disabilities that TD produces. Although a substantial
research has been stimulated to identify the underlying
pathophysiological mechanisms of TD, they remain
largely elusive. There are several hypotheses about the
pathophysiology of TD (dopamine hypersensitivity, neu-
rotoxicity, GABA insufficiency, noradrenergic dysfunc-
tion, structural abnormalities)[1], however the true
mechanism remains unknown.
The hypothesis of dopamine hypersensitivity proposes
that the nigrostriatal dopamine system develops increased
sensitivity to dopamine as a consequence of chronic
dopamine receptor blockade induced by neuroleptic
drugs. There is an increased incidence and prevalence of
involuntary hyperkinetic dyskinesia in patients receiving
dopamine antagonists in most [1-3] but not all reports
[4,5]. Dopamine antagonists usually suppress TD,
whereas dopamine agonists aggravate TD symptoms [6].
An alternate, though highly speculative hypothesis, is the
proposal that TD is due to neurotoxic effects induced by
free radical byproducts from catecholamine metabolism.
The basal ganglia, by virtue of their high oxidative metab-
olism, are vulnerable to membrane lipid peroxidation as
a result of the increased catecholamine turnover induced
by neuroleptic drugs [7-9]. It is known that vitamin E (a-
tocopherol) serves as a free radical scavenger, thus reduc-
ing the cytotoxic effects of free radicals. Clinical studies
have produced conflicting data in this area. The impres-
sion gained from these studies was that while vitamin E is
safe and well-tolerated, it confers only modest benefits.
Some studies do not support the hypothesis that TD is
mediated through free radical damage to neurons
[8,10,11] while others support that vitamin E appears to
be effective in reducing the severity of TD, especially in
patients who are young and have recently developed TD
[12,13].
Early neuroleptic agents showed great antipsychotic
promise initially, however, the induction of extrapyrami-
dal side effects associated with their use constituted a sig-
nificant problem. Atypical antipsychotics possess a lower
extrapyramidal side effects liability and show a better effi-
cacy in the treatment of negative and depressive symp-
toms as well as cognitive disorders associated with
schizophrenia. These features have been related to a
higher affinity to serotonin receptors. However, they
brought about various side effects such as weight gain,
hyperglycemia, cholesterol level elevation, and QT inter-
val prolongation [14].
A novel antipsychotic agent with a mechanism of action
different from all currently marketed typical and atypical
antipsychotics is aripiprazole. This quinoline derivative
exerts potent partial agonistic action on D2 and 5-HT1A
receptors and antagonistic properties at 5-HT2A receptors.
Aripiprazole claims to be the first agent of a third genera-
tion of antipsychotics, the so-called "dopamine-serotonin
stabilizers"[14].
In a previous study [15] we have shown that 6,7,8,9-tet-
rahydro-N,N,-di-n-propyl-1H-benz [g]indole-7-amine
(PBIA) (Figure 1) acts in vivo as a functional dopamine
receptor partial agonist. It is known that a partial agonist
at any dose level can not produce the same maximal bio-
logical response as a full agonist even though the partial
agonist binds as tightly and as well to the receptor as the
full agonist. In sum, a partial agonist has high affinity for
its receptor, but low intrinsic activity. PBIA is a moderate
[3H]-spiperone and 8-OH-[3H]-DPAT competitor. Spiper-
one is a selective D2 antagonist while 8-OH-DPAT is a
selective 5-HT1A agonist. This means that PBIA expresses a
moderate binding affinity at the dopamine D2 and serot-
onin 5-HT1A receptors in in vitro competition binding
assays.
PBIA was designed as a metabolically stable bioisostere of
the potent dopamine receptor agonist 5-OH-DPAT, (Fig-
ure 1). Phenolic dopamine receptor agonists suffer from
poor bioavailability due to rapid metabolic inactivation
via conjugation. Thus, an approach which has been pur-
sued to overcome this problem is to develop non phenolic
heterocyclic analogues. In this respect, evidence indicates
that an indole NH moiety can be a bioisostere of the
hydrogen-bonding H donor properties of the phenolic
OH group in dopamine agonists. Based on the above, we
synthesized PBIA.
In the present work, we tested the derivative 2 (Figure 1),
1-p-toluenesulfonyl-6,7,8,9-tetrhydro-N,N-di-n-propyl-
Structure of 6,7,8,9-tetrahydro-N,N,-di-n-propyl-1H-benz [g]indole-7-amine (PBIA), 1-p-toluenesulfonyl-6,7,8,9 t trhy-dro-N,N di-n-propyl-1H-benz [g]indol-7-amine (TPBIA) and 5-OH-DPATFigure 1
Structure of 6,7,8,9-tetrahydro-N,N,-di-n-propyl-1H-benz 
[g]indole-7-amine (PBIA), 1-p-toluenesulfonyl-6,7,8,9-tetrhy-
dro-N,N-di-n-propyl-1H-benz [g]indol-7-amine (TPBIA) and 
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in rats, related to interactions with central dopamine
receptors. Because TPBIA has an increased lipophilicity
and an appropriate polar molecular surface area (PSA)
value, we hypothesized that it might be capable of pene-
trating the blood-brain barrier in a considerable degree.
Additionally, the presence of the tosyl group might shift
the agonistic activity to that of an antagonist. It is docu-
mented that increasing the van der Waals molecular vol-
ume of an agonist makes it an antagonist [16]. Finally,
since free radical and oxidative stress may be implicated in
the pathophysiology of a number of neurodegenerative
diseases [17] we also investigated the antioxidant poten-
tial of TPBIA, since there are some reports concerning the
role of free radicals in TD [7].
Therefore, it becomes interesting to design compounds
that maintain antipsychotic efficacy and simultaneously
could be free of TD risk.
The aim of the current study was:
1) to find if TPBIA crosses the blood-brain barrier,
2) to test the behavioral effects of TPBIA with specific
focus on neuroleptic effects,
3) to test its antioxidant activity.
Materials and Methods
Synthesis of TPBIA
Key step of the synthesis was a Mukaiyama type aldol con-
densation between the dimethyl acetal of 1-(p-toluenesul-
fonyl)pyrrole-3-acetaldehyde and 4-di-n-propylamino-1-
trimethylsilyloxycyclohexene followed by cycloaromati-
zation under acidic conditions. A detailed description of
the procedures can be found elsewhere [18]. TPBIA was
isolated as its hydrochloride salt. It was a white crystalline
solid with melting point of 209–211°C. The salt was sol-
uble in water in contrast to its free base form.
Experimental Animals
Adult male Fischer-344 rats (~250 g) were used.
The experimental animals were grouped as:
i. Group A: Untreated rats: TPBIA was administered i.p. in
various doses and immediately afterwards the rats were
placed individually in the activity cage and their motor
behavior was recorded for the next 30 min.
ii. Group B: Apomorphine-treated rats: the motor activity was
measured as described above in the rats treated with apo-




The experiments were conducted according to a previous
reported methodology [15]. TPBIA was converted to its
hydrochloride salt and dissolved in water. Apomorphine
was dissolved in 1 mM citric acid solution. The motor
activity of the rats was measured between 12-6 pm in an
Ugo-Basile activity cage (type 7401) (Figure 2).
in vitro
The antioxidant potential of TPBIA was investigated in the
model of in vitro non enzymatic lipid peroxidation [19].
The experiments were conducted according to a previous
reported methodology [15]. Hepatic microsomal frac-
tions prepared from untreated male Fischer-344 rats were
heat-inactivated (90°C, 90 s) and suspended in Tris-HCl/
KCl buffer (50 mM/150 mM, pH 7.4). The incubation
mixtures contained the microsomal fraction, correspond-
ing to 0.125 g liver mL-1, ascorbic acid (0.2 mM) in Tris
buffer, and various concentrations (0.01–1 mM) of the
tested compounds dissolved in DMSO. An equal volume
of the solvent (0.1 mL) was added to the control incubate.
The Ugo-Basile activity cage (type 7401)Figure 2
The Ugo-Basile activity cage (type 7401)Page 3 of 7
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FeSO4 solution (10 µM). The mixture was incubated at
37°C for 45 min. Aliquots (0.3 mL) of the incubation
mixture (final volume 4 mL) were taken at various time
intervals. Lipid peroxidation was assayed spectrophoto-
metrically (535 nm against 600 nm) by determination of
the 2-thiobarbituric acid reactive material.
Antioxidants inhibit the production of malondialdehyde
and, therefore, the color produced after addition of 2-
thiobarbituric acid is less intense. None of the com-
pounds interfered with the assay, neither with the conju-
gation of 2-thiobarbituric acid or with the absorption at
535–600 nm. Each experiment was performed at least in
duplicate. The UV measurements were carried out on a
Perkin-Elmer 554 spectrophotometer.
Results
The effect of the TPBIA on the motor behavior of non
treated and apomorphine pretreated rats are shown in
Tables 1, 2 and Figure 3. Apomorphine is a selective ago-
nist of the dopamine D2 receptors. It was found that:
i. In non-pretreated rats, TPBIA at doses of 40 and 80
µmol/kg reduces the activity by 39 and 82% respectively
(Number of experimental animals: 3–6).
ii. In apomorphine pretreated rats, TPBIA (80 µmol/kg)
reverses the hyperactivity and stereotype behavior
induced by apomorphine (Number of experimental ani-
mals: 4).
The time course of non enzymatic lipid peroxidation as
affected by 0.5, 0.25 and 0.1 mM concentrations of TPBIA
is shown in Figure 4.
Discussion
The results support our hypothesis that:
a) TPBIA crosses the blood-brain barrier,
b) modifies the motor behavior of the experimental
animals,
c) shows antioxidant activity.
a) The Polar Surface Area (PSA) of a molecule is defined
as the area of its van der Waals surface that arises from
oxygen and nitrogen atoms as well as hydrogen atoms
attached to oxygen or nitrogen atoms. As such, it is clearly
related to the capacity of a compound to form hydrogen
bonds. PSA has been established as a valuable physico-
chemical parameter for the prediction of a number of
properties related to the pharmacokinetic profile of drugs.
Among these properties are the intestinal absorption and
the blood-brain barrier penetration. PSA has been found
to be useful in modeling intestinal absorption together
with a direct estimate of lipophilicity widely acknowl-
edged as an important factor in transport across
membranes. A common measure of the degree of BBB
penetration is the ratio of the steady-state concentrations
of the drug molecule in the brain and in the blood, usu-
ally expressed as log(Cbrain/Cblood). We expect that the
increased lipophilicity (calculated [20] ClogP = 6.659)
and the small PSA value (calculated [21], 38.9
Angstroems2) of this compound will facilitate its central
Table 1: Motor behavior of untreated rats




NS, P > 0.05 (not significant) and **P < 0.01 according to Student's test, n = 3–6
Table 2: Motor behavior of apomorphine treated rats
Compound (dose, µmol Kg-1) Movements (± SEM) / 30 min Compared with the control group (%)
Apomorphine treated controls 385(68) 100
TPBIA(80) 113(28)** 29
**P < 0.01 according to Student's test, n = 4Page 4 of 7
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reported by Clark et al [22] we found that the steady-state
distribution of TPBIA between brain and blood is approx-
imately 1000/1 (logBB = 0.58). This computational
model contains two variables: PSA and calculated logP,
both of which can be rapidly computed. The model could
be considered reliable; for example the measured and pre-
dicted BBB permeability of the antidepressant drug, amit-
ryptyline were quite similar (experimental logBB = 0.76–
0.98 and calculated logBB = 0.76). Finally, its low PSA
value is a strong indication that it could be used per os for
systematic use [23].
b) The presented results could suggest that TPBIA acts as
a dopamine receptor antagonist in the central nervous sys-
tem. The tosyl group in TPBIA, which plain was found to
be perpendicular to that of the indole ring in its low
energy conformation (Figure 4) [24] is important to the
differentiation of the biological profile between com-
pounds PBIA and TPBIA. The association of increasing
molecular weight with increasing antagonistic power is
well known. An antagonist is always bulkier than the
corresponding agonist and it is obvious that the likeli-
hood of forming extra van der Waals bonds with the
receptor increases the chances of the bulkier molecule
having a longer retention time. Because a molecule's
kinetic energy of translation (which is an important factor
in desorption) does not change with increase in molecular
weight, any gain in size by the molecule increases its time
of residence on the receptor [16].
c) Some clinical studies [6,25] have shown that vitamin E
(a well established antioxidant) may be effective in
treating TD. However vitamin E does not cross readily the
blood-brain barrier [26], which could explain why other
studies failed to confirm these results [6]. Therefore we
considered interesting to investigate the antioxidant
potential of the synthesized TPBIA. It was found that
TPBIA completely inhibits the peroxidation of rat liver
microsome preparations at the studied concentrations
Conclusion
The results of the current study suggest that TPBIA crosses
the blood-brain barrier, possesses neuroleptic activity and
exerts antioxidative activity. The above constitute prelimi-
nary in vivo/vitro evidence suggesting that TPBIA could
Effect of TPBIA on the motor behavior of experimental animalsFigure 3
Effect of TPBIA on the motor behavior of experimental animalsPage 5 of 7
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antipsychotic agent with novel and clinically important
properties.
A putative combination of dopaminergic antagonism and
antioxidant activity of a compound which readily cross
the blood-brain barrier could be of pharmaceutical inter-
est especially when the compound is used for the treat-
ment of behavioral disorders in the frame of an organic or
degenerative mental disorder.
The above results indicate that TPBIA might have thera-
peutic potential in the treatment of psychosis, due to its
dopamine antagonistic activity in the central nervous sys-
tem. In addition, its antioxidant effects is a desirable prop-
erty, since tardive dyskinesia – a neuroleptics' severe side
effect – has been attributed, at least in part, to oxidative
stress.
Time course of lipid peroxidation as affected by various concentrations of TPBIAF gure 4
Time course of lipid peroxidation as affected by various concentrations of TPBIA.
Low energy conformation and van der Waals surface of com-p und TPBIAFigure 5
Low energy conformation and van der Waals surface of com-
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